Clinical Trial Update: EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial [Phase 4]

View source ↗

Summary

Phase 4 trial updating on expanded combination of evolocumab with empagliflozin for dyslipidemia in type 2 diabetes; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia Associated with Type Ii Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)
• Evolocumab (evolocumab)

Snippet

Sponsor: University of Campinas, Brazil | Conditions: Dyslipidemia Associated With Type II Diabetes Mellitus, Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED